Search Results

Containing any of the words

Only of the type

Biotin,Cyanocobalamin,Folic Acid,Nicotinamide,Pyridoxine (Vitamin B6),Riboflavin,Sodium Ascorbate,Sodium Pantothenate,Thiamine New SFDA Drug Approvals

An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Drug Clinical Trial

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma Drug Clinical Trial

An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Dexaflox Eye Drops Containing Ofloxacin (3 mg) and dexamethasone (1 mg) in Subjects with Bacterial Conjunctivitis Drug Clinical Trial

Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis Drug Clinical Trial

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) Drug Clinical Trial

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma Drug Clinical Trial

An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Drug Clinical Trial

Recent Study Indicates A Higher Risk of Heart Attack In Patients Infected With HIV-1 Taking Ziagen (Abacavir) and Videx (Didanosine) Awareness Article

In an Online Questionnaire launched by SFDA: 73% of respondents are not keen to report about counterfeit or expired products News